Literature DB >> 16876255

Treating insomnia: Current and investigational pharmacological approaches.

Bjarke Ebert1, Keith A Wafford, Stephen Deacon.   

Abstract

Chronic insomnia affects a significant proportion of young adult and elderly populations. Treatment strategies should alleviate nighttime symptoms, the feeling of nonrestorative sleep, and impaired daytime function. Current pharmacological approaches focus primarily on GABA, the major inhibitory neurotransmitter in the central nervous system. Benzodiazepine receptor agonists (BzRA) have been a mainstay of pharmacotherapy; the classical benzodiazepines and non-benzodiazepines share a similar mode of action and allosterically enhance inhibitory chloride currents through the GABA(A) receptor, a ligand-gated protein comprising 5 subunits pseudosymmetrically arranged around a core anion channel. Variations in GABA(A) receptor subunit composition confer unique pharmacological, biophysical, and electrophysiological properties on each receptor subtype. Classical benzodiazepines bind non-selectively to GABA(A) receptors containing a gamma2 subunit, whereas non-benzodiazepine hypnotics bind with higher relative affinity to alpha1-containing receptors. The non-benzodiazepine compounds generally represent an improvement over benzodiazepines as a result of improved binding selectivity and pharmacokinetic profiles. However, the enduring potential for amnestic effects, next day residual sedation, and abuse and physical dependence, particularly at higher doses, underscores the need for new treatment strategies. Novel pharmacotherapies in development act on systems believed to be specifically involved in the regulation of the sleep-wake cycle. The recently approved melatonin receptor agonist, ramelteon, targets circadian mechanisms. Gaboxadol, an investigational treatment and a selective extrasynaptic GABA(A) receptor agonist (SEGA), targets GABA(A) receptors containing a delta subunit, which are located outside the synaptic junctions of thalamic and cortical neurons thought to play an important regulatory role in the onset, maintenance, and depth of the sleep process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16876255     DOI: 10.1016/j.pharmthera.2005.04.014

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  33 in total

1.  EEG power spectra response to a 4-h phase advance and gaboxadol treatment in 822 men and women.

Authors:  Junshui Ma; Derk-Jan Dijk; Vladimir Svetnik; Yevgen Tymofyeyev; Shubhankar Ray; James K Walsh; Steve Deacon
Journal:  J Clin Sleep Med       Date:  2011-10-15       Impact factor: 4.062

2.  The Use of Benzodiazepine Receptor Agonists and Risk of Respiratory Failure in Patients with Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Case-Control Study.

Authors:  Su-Jung Chen; Chiu-Mei Yeh; Tze-Fan Chao; Chia-Jen Liu; Kang-Ling Wang; Tzeng-Ji Chen; Pesus Chou; Fu-Der Wang
Journal:  Sleep       Date:  2015-07-01       Impact factor: 5.849

3.  Clinical relevance of disturbances of sleep and vigilance in major depressive disorder: a review.

Authors:  Michael E Thase; Harald Murck; Anke Post
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 4.  The sleep relay--the role of the thalamus in central and decentral sleep regulation.

Authors:  Philippe Coulon; Thomas Budde; Hans-Christian Pape
Journal:  Pflugers Arch       Date:  2011-09-13       Impact factor: 3.657

Review 5.  Control of sleep and wakefulness.

Authors:  Ritchie E Brown; Radhika Basheer; James T McKenna; Robert E Strecker; Robert W McCarley
Journal:  Physiol Rev       Date:  2012-07       Impact factor: 37.312

6.  Effectiveness of Benzodiazepine Receptor Agonists in the Treatment of Insomnia: An Examination of Response and Remission Rates.

Authors:  Vivek Pillai; Thomas Roth; Timothy Roehrs; Kenneth Moss; Edward L Peterson; Christopher L Drake
Journal:  Sleep       Date:  2017-02-01       Impact factor: 5.849

7.  Effect of gaboxadol on sleep in adult and elderly patients with primary insomnia: results from two randomized, placebo-controlled, 30-night polysomnography studies.

Authors:  D Alan Lankford; Bruce C Corser; Yan-Ping Zheng; Zhengrong Li; Duane B Snavely; Christopher R Lines; Steve Deacon
Journal:  Sleep       Date:  2008-10       Impact factor: 5.849

8.  Context dependent benzodiazepine modulation of GABA(A) receptor opening frequency.

Authors:  Matt T Bianchi
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

9.  Distinct α subunit variations of the hypothalamic GABAA receptor triplets (αβγ) are linked to hibernating state in hamsters.

Authors:  Raffaella Alò; Ennio Avolio; Anna Di Vito; Antonio Carelli; Rosa Maria Facciolo; Marcello Canonaco
Journal:  BMC Neurosci       Date:  2010-09-06       Impact factor: 3.288

10.  Eszopiclone: its use in the treatment of insomnia.

Authors:  Jaime M Monti; S R Pandi-Perumal
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.